FG
FGHQF.US Frontage Holdings Corporation
- Market cap
- USD 356M
- P/E
- 17.5x
- P/B
- 1.00x
- ROE
- 7.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is FGHQF.US undervalued?
Graham numberFGHQF.US trades 11.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Frontage Holdings Corporation fundamental analysis
No fundamental analysis for Frontage Holdings Corporation yet.
Frontage Holdings Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Frontage Holdings Corporation
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early p…
Full company profileFrontage Holdings Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Frontage Holdings Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 48.6M | 70.2M | 83.1M | 101M | 126M | 184M | 251M | 260M | 255M | 257M | 591M |
| Gross Profit | 19.3M | 31.1M | 33.9M | 37.5M | 41.5M | 66.5M | 89.4M | 78.4M | 69.8M | 69.3M | 151M |
| Operating Income | 10.4M | 19.9M | 13.1M | 15.6M | 15.7M | 25.2M | 33.2M | 20.2M | 9.34M | 14.6M | 52.3M |
| EBITDA | - | 19.5M | 18.8M | 29.8M | 34.0M | 51.6M | 69.9M | 57.2M | 49.9M | 49.5M | 127M |
| Net Income | 6.65M | 10.2M | 11.2M | 18.4M | 17.2M | 18.4M | 25.7M | 10.8M | 791K | 6.80M | 26.9M |
| EPS | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 42.6M | 57.2M | 77.5M | 315M | 383M | 476M | 550M | 572M | 554M | 541M | 580M |
| Total Liabilities | 23.9M | 27.0M | 33.8M | 50.0M | 93.8M | 153M | 215M | 227M | 219M | 191M | 222M |
| Shareholders' Equity | 18.8M | 30.2M | 43.6M | 265M | 288M | 320M | 333M | 343M | 333M | 347M | 355M |
| Cash & Short-term Investments | 3.25M | 4.34M | 16.3M | 208M | 215M | 149M | 90.8M | 54.6M | 44.1M | 39.1M | 36.8M |
| Total Debt | - | - | - | 20.9M | 40.6M | 57.8M | 118M | 145M | 154M | 128M | 141M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 9.35M | 6.76M | 22.7M | 20.1M | 31.7M | 44.5M | 62.3M | 39.7M | 40.6M | 43.9M | 103M |
| Capital Expenditure | 4.02M | 3.22M | 5.22M | 13.9M | 15.1M | 50.5M | 48.2M | 21.2M | 25.7M | 11.7M | 24.8M |
| Free Cash Flow | - | 3.54M | 17.4M | 6.18M | 20.8M | -4.13M | 14.1M | 18.6M | 15.0M | 32.3M | 77.8M |
| Ratios | |||||||||||
| ROE | 35.4% | 33.6% | 25.8% | 7.0% | 6.0% | 5.8% | 7.7% | 3.2% | 0.2% | 2.0% | 7.6% |
| ROA | 15.6% | 17.8% | 14.5% | 5.8% | 4.5% | 3.9% | 4.7% | 1.9% | 0.1% | 1.3% | 4.6% |
| Net Profit Margin | 13.7% | 14.5% | 13.5% | 18.2% | 13.6% | 10.0% | 10.3% | 4.2% | 0.3% | 2.6% | 4.6% |
| Debt to Equity | - | - | - | 0.08x | 0.14x | 0.18x | 0.35x | 0.42x | 0.46x | 0.37x | 0.40x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Frontage Holdings Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 10.5M | 0.01 | 40.8% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Frontage Holdings Corporation
- Insiders 73.78%
- Institutions 0.15%
- Public & others 26.07%
- Shares outstanding 2.03B
- Free float 529M
Frontage Holdings Corporation company profile
- Company name
- Frontage Holdings Corporation
- Ticker
- FGHQF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,800
- Fiscal year end
- December
- Address
- 700 Pennsylvania Drive, Exton, PA, United States, 19341
- Phone
- 610 232 0100
- Website
- frontagelab.com
About Frontage Holdings Corporation
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies. It offers drug discovery services comprising medicinal chemistry, pharmacology, and efficacy, as well as absorption, distribution, metabolism, and excretion (ADME) screening. The company also provides drug metabolism and pharmacokinetics (DMPK); safety and toxicology; early phase clinical services; and bioequivalence and related services, such as pharmacology, medical writing, and regulatory support. In addition, it offers pharmaceutical product development services, including intermediate and active pharmaceutical ingredient (API) synthesis, process and formulation development, and clinical trial material manufacturing. Further, the company provides laboratory testing services, such as bioanalysis, biomarkers, genomics, chemistry, manufacturing and controls ("CMC") analytical testing, and central laboratory services. It operates in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was founded in 2001 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation operates as a subsidiary of Hongkong Tigermed Consulting Co., ltd.
Frontage Holdings Corporation management
9- Dr. Song Li M.D., Ph.D.Founder & Chairman · born 1957
- Dr. Zhongping Lin Ph.D.Co-CEO Executive & Director · born 1964
- Dr. Wentao Zhang Ph.D.Co-CEO & Executive Director · born 1969
- Dr. Abdul Ezaz Mutlib Ph.D.Chief Scientific & Strategy Officer and President of Frontage Laboratories of Canada · born 1961
- Ms. Huan WangInterim Chief Financial Officer · born 1986
- Dr. Dongmei Wang Ph.D.Executive Vice President of Global Sales & Marketing · born 1965
- Dr. Tianyi ZhangSenior VP of the Group & GM of Frontage Shanghai · born 1969
- Mr. Sudendra Rao Ph.D.Senior Vice President of Human Resources - North America
- Dr. John Kapeghian Ph.D.Executive Vice President of Global Safety & Toxicology